Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
Developer Embark Studios releases a new ARC Raiders update for January 2026, as patch 1.11.0 brings some big balance ...
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in ...
If you don’t use a trackpad or Magic Mouse, you can set up Hot Corners to zip around your Mac. Image: D. Griffin Jones/Cult of Mac Mac Hot Corners are shortcuts for your mouse. Enable the Hot Corners ...
Dungeons & Dragons' bloody handed new subclass is part Bhaalspawn, part Dark Urge, all teleporting terror - here's how to ...
Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...
Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in ...
Indeed, this question was posed directly to Rebel Wolves creative director Mateusz Tomaskiewicz this week. In an interview ...
As medical device manufacturers face mounting pressures to reduce environmental risk, improve traceability, and accelerate ...
The Torchlight Infinite Vorax season adds new grafting mechanics, high-risk hero Vendetta Erika, and a UI overhaul to make it ...
A significant milestone in Ocugen's development of a gene therapy for Stargardt disease has triggered a substantial rally in the company's stock. The catalyst was the publication of positive Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback